Drug Trial Radar · NCT06532006
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
550
Planned (sponsor's estimate)
Start
Nov 22, 2024
Primary completion
Jun 1, 2027
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- Collaborators
- Henlius USA
- First posted
- Aug 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with HER2-positive locally advanced/metastatic adenocarcinoma of the gastric and/or gastroesophageal junction (G/GEJ).Eligible subjects will be randomized to the two groups based on a 1:1 ratio. Enrolled subjects shall be treated with the study drug until the loss of clinical benefit, death, intolerable toxicity, withdrawal of informed consent, or other reasons specified by the protocol (whichever occurs first).
Conditions
- Gastroesophageal-junction Cancer
- Monoclonal Antibody
- Gastric Cancer
- HER2-positive Gastric Cancer
Interventions
HLX22Drug
HLX22 15mg/kg Q3w
PembrolizumabDrug
Pembrolizumab 200mg q3w
TrastuzumabDrug
Trastuzumab 8 mg/kg loading dose and then 6 mg/kg maintenance thereafter ,Q3W
OxaliplatinDrug
Oxaliplatin 130 mg/m2 ,Q3W
CapecitabineDrug
Capecitabine 1000 mg/m2 bid on Days 1-14 ,Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)per RECIST 1.1 assessed by IRRC(Independent Radiology Review Committee)Time frame: Up to 5 years
- Overall Survival (OS)Time frame: Up to 5 years
Locations
208 sites in 17 countries. Site status is shown where the registry gives one.
Los Angeles Cancer Network
Anaheim, California · Recruiting
OPN - Oncology Physician Network (Los Alamitos)
Los Alamitos, California · Recruiting
Banner MD Anderson Cancer Center
Greeley, Colorado · Recruiting
Advanced Research LLC
Deerfield Beach, Florida · Recruiting
Florida Cancer Specialist - South
Fort Myers, Florida · Recruiting
BRCR Medical Center
Plantation, Florida · Recruiting
Napa Research
Pompano Beach, Florida · Recruiting
Florida Cancer Specialist - North
St. Petersburg, Florida · Recruiting
Florida Cancer Specialist - East
West Palm Beach, Florida · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
Mission Cancer + Blood (Exigent Network)
Des Moines, Iowa · Recruiting
Holden Comprehensive Cancer Center - University of Iowa
Iowa City, Iowa · Recruiting
Washington University School of Medicine St. Louis
St Louis, Missouri · Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
Comprehensive Cancer Centers Nevada
Las Vegas, Nevada · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Guthrie Medical Group, PC and Robert Packer Hospital (Guthrie Cancer Center - Sayre)
Sayre, Pennsylvania · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
HCA Midwest Health
Nashville, Tennessee · Recruiting
Texas Oncology - West (SCRI)
Abilene, Texas · Recruiting
Texas Oncology Central South (SCRI)
Austin, Texas · Recruiting
Texas Oncology Northeast (SCRI)
Denton, Texas · Recruiting
The University of Texas MD Anderson cancer Center
Houston, Texas · Recruiting
Texas Oncology - Gulf Coast (SCRI)
Webster, Texas · Recruiting
American Oncology Network Vista Oncology Division
Olympia, Washington · Recruiting
Northwest Medical Specialties
Tacoma, Washington · Recruiting
West Virginia University Cancer Institute
Morgantown, West Virginia · Recruiting
Fundacion CENIT
Buenos Aires, Argentina · Recruiting
IONC Instituto Oncologico de Cordoba
Córdoba, Argentina · Recruiting
Instituto San Marcos
San Juan, Argentina · Recruiting
CER - Centro de Rehabilitacion Medica San Juan
San Juan, Argentina · Recruiting
Exelsus
San Miguel de Tucumán, Argentina · Recruiting
Centro de Investigacion Pergamino SA
Buenos Aires, Buenos Aires, Argentina · Recruiting
Centro de Investigaciones Clinicas. Clinica Viedma S.A.
Viedma, Río Negro Province, Argentina · Recruiting
União Brasileira de Educação e Assistência
Puerto Alegre, RS, Argentina · Recruiting
Instituto de Oncologia de Rosario
Cordoba, Santa Fe Province, Argentina · Recruiting
Centro Médico Privado CEMAIC
Cordoba, Santa Fe Province, Argentina · Not yet recruiting
Sanatorio Plaza - Fundacion Pita
Rosario, Santa Fe Province, Argentina · Recruiting
Showing 40 of 208 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.